Thyrocare Technologies is India’s largest fully automated diagnostic laboratory - an IT-driven, high-volume testing engine that processes more tests than some of its biggest competitors combined, all built on the belief that diagnostics should be a necessity, not a privilege. Founded in 1996 with just three thyroid tests by a former BARC scientist, the company spent two decades scaling a low-cost, franchisee-fed hub-and-spoke model before a 2021 acquisition by API Holdings (the entity behind PharmEasy) ushered in new management and a deliberate pivot from a pure preventive-testing player into a full-spectrum diagnostics house covering everything from allergy and genomics to histopathology. The recurring approach is a volume-first, asset-heavy back end paired with a capital-light, franchisee-driven front end - Thyrocare runs the labs and logistics, while thousands of independent collection points bring in the samples. # Business segments Two engines at different stages - a high-volume pathology cash cow that is the heart of the business, and a small, capex-intensive radiology bet built on a cyclotron and a handful of imaging centres. ## 1. Pathology testing: the high-volume, low-cost lab that powers the franchisee network **Thyrocare runs a hub-and-spoke network of 40 automated laboratories that processed 210 million tests in FY26, earning a per-test fee while its franchisee partners own the customer relationship.** - **Samples flow in, reports flow out** - franchisee collection centres and doorstep phlebotomists gather samples across more than 5,400 pin codes; the samples are aggregated and routed to the nearest lab, with 67% reaching a Thyrocare facility within 12 hours. The average turnaround time from sample receipt to report is just 3.43 hours because labs run 24×7 on barcoded, bi-directionally-interfaced automation. - **The lab hierarchy creates operating leverage** - two Central Processing Labs in Navi Mumbai and Delhi handle the most advanced work, while 21 Regional, 2 Zonal, and 6 Satellite labs process routine tests closer to collection points, so incremental volumes from new franchisees flow into existing infrastructure rather than requiring new builds. Seven new labs opened in FY26 in towns like Bhagalpur, Mandi, and Davanagere, pushing deeper into Tier 2 and Tier 3 markets. - **Quality at Six Sigma levels** - 97% of samples are processed in NABL-accredited owned laboratories, every report is reviewed by a qualified MD Pathologist, and complaints run at 3.06 per million tests, a benchmark the company claims as an Indian diagnostic-industry first. The company was the first Indian diagnostic chain to achieve 100% NABL accreditation across all owned labs. - **Earned per test, not per patient** - revenue per test (excluding materials) was ₹36.1 in FY26, with patients averaging 10.9 tests each, making the economics a pure volume game where scale drives affordability. The test menu has expanded from 636 distinct tests in FY22 to over 1,275 in FY26, spanning thyroid, diabetes, infectious disease, cardiac, oncology markers, histocytology, allergy, genomics, and more. - **A revamped machine fleet** - in FY24 the company replaced machines averaging 12 years of age with over 30 new ones, bringing the average age down to six years and improving both accuracy and turnaround time. New platforms added in FY26 include Next Gen sequencing, ImmunoCAP for allergy, and BioFire panels. ## 2. Radiology and imaging: a small PET-CT network with its own isotope supply **Thyrocare’s radiology business runs 10 PET-CT scanners for cancer monitoring and a handful of general-radiology centres, anchored by a cyclotron in Navi Mumbai that makes its own radioactive tracer.** - **Backward integration into the tracer** - the subsidiary Nueclear Healthcare owns and operates a medical cyclotron licensed by the Atomic Energy Regulatory Board that produces FDG (the radioactive biomarker used in PET-CT scans), giving it control over supply, reliability, and cost in a way most standalone imaging centres cannot match. - **A focused cancer-imaging footprint** - 10 active PET-CT scanners across cities including Delhi, Mumbai, Hyderabad, and Bengaluru performed 31,505 scans in FY24, with the business generating ₹44.62 crore in revenue and a modest operating EBITDA of ₹6.16 crore in FY26. # Group structure and partners **Thyrocare sits inside the API Holdings (PharmEasy) ecosystem, with a 71% stake held by Docon Technologies, and has expanded through small, targeted acquisitions that add capabilities rather than scale alone.** - **Docon Technologies is a subsidiary of API Holdings Limited** - Docon Technologies acquired 66.14% from the founding promoter group in June 2021 for ₹4,546 crore, and the original promoters exited entirely by March 2022. Rahul Guha serves as MD & CEO of Thyrocare while also holding the role of President of Operations at API Group. - **PharmEasy is a distribution channel** - the online pharmacy accounted for 12% of pathology revenue as of late 2022, and sister platforms like Retailio (a B2B retailer app) have onboarded 2,500 pharmacy counters that placed at least one diagnostic order. Aknamed, another group company supplying consumables to 900 hospitals, opens doors for hospital diagnostic contracts. - **Acquisitions fill capability gaps** - Think Health Diagnostics (acquired 2024) added at-home ECG testing serving the insurance sector; Polo Labs (2024) brought presence in Punjab, Haryana, and Himachal; and Vimta Labs’ clinical diagnostics business (2024) added 11 centres and a NABL-accredited Hyderabad lab. - **International is a single-lab bet in Tanzania** - Thyrocare Laboratories (Tanzania) Limited, originally a 50:50 joint venture with the Kastipharm Group, became a subsidiary as Thyrocare’s investment crossed the halfway mark; it now holds 57.25% equity and serves over 150 healthcare facilities in Dar es Salaam, with turnover of ₹1.84 crore for the year ended December 2025.